Jan Drappatz MD; Elizabeth Maher, MD, PhD; Alexandra M. Miller, MD, PhD; and David Reardon, MD discuss how the 2021 WHO classification emphasizing molecular markers like IDH mutations has transformed glioma treatment from a histology-based approach to personalized therapy, with IDH inhibitors offering new first-line options that can defer radiation and chemotherapy while maintaining quality of life for patients with IDH-mutant gliomas.
EP. 1: Redefining Gliomas Through Molecular Classification
July 25th 2025Panelists discuss how the 2021 WHO classification has fundamentally shifted glioma diagnosis from histologic appearance to molecular markers, particularly IDH mutation status, which now determines treatment strategies and prognosis.
EP. 2: Treatment Workflow for IDH-Mutant Gliomas
July 25th 2025Panelists discuss how they approach the treatment journey by prioritizing early IDH mutation detection, coordinating multidisciplinary teams for maximal safe resection, and utilizing advanced surgical techniques to optimize outcomes while preserving neurologic function.